allergytalk

• Episode 5: Risk Factors for Venom Allergy, Triggers for Adult-onset Asthma and Associations Between Pollution and ED Visits

This is part 2 of our summaries from the July-August 2019 issue of Allergy Watch:

Investigation of the factors that determine the severity of allergic reactions to Hymenoptera venoms

https://www.ncbi.nlm.nih.gov/pubmed/30819281

New-Onset Asthma in Adults: What Does the Trigger History Tell Us?

https://www.ncbi.nlm.nih.gov/pubmed/30240884

Age-Specific Associations of Ozone and Fine Particulate Matter with Respiratory Emergency Department Visits in the United States

https://www.ncbi.nlm.nih.gov/pubmed/30277796

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Dr. Lee was on an advisory board for Teva.

Dr. Kalangara has received consulting fees from AstraZeneca.

Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.

Episode 4: Dupliumab for Nasal Polyps, Cockroach Immunotherapy and Immediate Food Allergy in EoE

For today’s episode we will be reviewing three articles from the July-August 2019 issue of Allergy Watch:

Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis

https://www.ncbi.nlm.nih.gov/pubmed/30488542

Allergen content in German cockroach extracts and sensitization profiles to a new expanded set of cockroach allergens determine in vitro extract potency for IgE reactivity

https://www.ncbi.nlm.nih.gov/pubmed/30170124

New IgE immediate hypersensitivity reactions on reintroduction of food restricted for treatment of eosinophilic esophagitis

https://www.ncbi.nlm.nih.gov/pubmed/30684739

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Dr. Lee was on an advisory board for Teva.

Dr. Kalangara has received consulting fees from AstraZeneca.

Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.

Episode 3: Food Allergy & Eczema

For today’s episode we will be reviewing three articles about food allergy and eczema from the May-June 2019 issue of Allergy Watch:

• The Basophil Activation Test reduces the need for a food challenge test in children suspected of IgE-mediated cow's milk allergy.
  https://www.ncbi.nlm.nih.gov/pubmed/30408255
• Oral food challenge failures among foods restricted because of atopic dermatitis.
  https://www.ncbi.nlm.nih.gov/pubmed/30326323
• The nonlesional skin surface distinguishes atopic dermatitis with food allergy as a unique endotype.
  https://www.ncbi.nlm.nih.gov/pubmed/30787169

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Dr. Lee was on an advisory board for Teva.

Dr. Kalangara has received consulting fees from Astra Zenica.

Dr. Fineman 
Speaker: AstraZenca, Boehringer Ingelheim, Shire
Research: Aimmune, DBV, Shire, Regeneron.

Episode 2: Asthma

For today’s episode we will be reviewing three articles about asthma from the May-June 2019 issue of Allergy Watch:

• Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis.
  https://www.ncbi.nlm.nih.gov/pubmed/30217529
• Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison.
  https://www.ncbi.nlm.nih.gov/pubmed/30205189
• Indirect Treatment Comparisons and Biologics
  https://www.ncbi.nlm.nih.gov/pubmed/30612667
• Endotypes of severe allergic asthma patients who clinically benefit from anti?IgE therapy
  https://www.ncbi.nlm.nih.gov/pubmed/30107059/
• Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma
  https://www.ncbi.nlm.nih.gov/pubmed/29301922

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Dr. Lee was on an advisory board for Teva.

Dr. Kalangara has received consulting fees from Astra Zenica.

Dr. Fineman 
Speaker: AstraZenca, Boehringer Ingelheim, Shire
Research: Aimmune, DBV, Shire, Regeneron.

Episode 1

With guest Stanley Fineman, MD, MBA, FACAAI, editor-in-chief of AllergyWatch.